Increasing Diversion of Methadone in Vancouver, Canada, 2005-2015

Peer reviewed: 
Yes, item is peer reviewed.
Scholarly level: 
Faculty/Staff
Final version published as: 

Reddon H, Ho J, DeBeck K, Milloy MJ, Yang L, Dong H, Ahamad K, Wood E, Kerr T, Hayashi K. Increasing diversion of methadone in Vancouver, Canada, 2005-2015. Journal of Substance Abuse Treatment, 2018 85 (Feb.) 10-16 (Epub 2017 Nov 28).  https://doi.org/10.1016/j.jsat.2017.11.010

Date created: 
2017-11-28
Identifier: 
DOI: 10.1016/j.jsat.2017.11.010
Keywords: 
Methadone
Diversion
Opioid
Overdose
Illicit drug use
Abstract: 

Background and Aim: Although methadone, an opioid agonist, has been an effective medication used to treat opioid use disorder for over 40 years, recent studies have found that methadone was identified in more than a quarter of prescription opioid-related deaths among people who use illicit drugs in Vancouver, Canada. Thus, we sought to longitudinally examine the availability of diverted methadone among people who inject drugs (PWID).

Design and Methods: Data were collected from three prospective cohorts of PWID in Vancouver, Canada between December 2005 and May 2015. Multivariable generalized estimating equation logistic regression was used to identify temporal trends in the immediate availability of diverted methadone (defined as the ability to acquire illicit methadone in <10 minutes).

Results: A total of 2092 participants, including 727 (34.8%) women, were included in the present study. In the multivariable analyses after adjusting for a range of potential confounders, later calendar year (adjusted odds ratio [AOR] = 1.21 per year; 95% confidence interval [CI]: 1.19–1.23) was independently and positively associated with reporting immediate availability of diverted methadone.

Conclusions: We observed a significant increase in the reported availability of diverted methadone among PWID over a ten-year follow-up period. Further research is needed to identify strategies to limit methadone diversion and assess the impact of alternative medications that are equally effective but safer, such as buprenorphine/naloxone.

Description: 

The full text of this paper will be available December 2018 in keeping with the embargo period of the Journal of Substance Abuse Treatment. If you require access to the full text prior to December 2018, please contact summit@sfu.ca.

Language: 
English
Document type: 
Article
Rights: 
Rights remain with the authors.
Sponsor(s): 
US National Institutes of Health
Canadian Institutes of Health Research
Michael Smith Foundation
St. Paul’s Hospital Foundation
Statistics: